https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Rigel_Pharmaceuticals%2C_Inc.Rigel Pharmaceuticals, Inc. - Revizia istoricului2026-05-18T18:12:12ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Rigel_Pharmaceuticals,_Inc.&diff=438475&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Rigel Pharmaceuticals, Inc. listata cu simbolul US.RIGL ==Descriere companie== Rigel Pharmaceuticals, Inc. (https://www.rigel.com/) is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's prod...2024-09-18T18:25:30Z<p>Pagină nouă: Pagina dedicata companiei Rigel Pharmaceuticals, Inc. listata cu simbolul US.RIGL ==Descriere companie== Rigel Pharmaceuticals, Inc. (https://www.rigel.com/) is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's prod...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Rigel Pharmaceuticals, Inc. listata cu simbolul US.RIGL<br />
<br />
==Descriere companie==<br />
Rigel Pharmaceuticals, Inc. (https://www.rigel.com/) is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its clinical program, Fostamatinib is being studied in a Phase III trial for the treatment of warm autoimmune hemolytic anemia (wAIHA). The Company's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.RIGL" /><br />
<br />
==Ultimele stiri despre Rigel Pharmaceuticals, Inc. (US.RIGL)==<br />
<dynamicpagelist><br />
category=US.RIGL<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.RIGL]][[Categorie:Stiri despre companii]]</div>Admin